Fuso Pharmaceutical Industries said the Lixelle dialysis product contributed to higher revenue and released its first-half FY2026 results. In response, the company revised its full-year forecasts upward and raised its year-end dividend by ¥1 to ¥46 per share, setting its full-year dividend at ¥91 per share.
Fuso Pharmaceutical Industries held its first-half FY2026 results briefing and indicated that it expects to raise its full-year forecasts based on its first-half results. The company also disclosed plans to increase its dividend.
First-half revenue was ¥32,395 million, operating profit was ¥1,743 million, ordinary profit was ¥1,434 million and net income was ¥1,041 million, with all four measures increasing year on year.
Following its first-half results, the company revised its full-year forecasts upward to revenue of ¥64,800 million, operating profit of ¥2,400 million, ordinary profit of ¥1,800 million and net income of ¥1,500 million, respectively. The contribution from the Lixelle dialysis product is expected to continue, and attention will focus on performance trends in the second half.
As part of its shareholder return policy, the company raised its year-end dividend to ¥46 per share and expects a full-year dividend of ¥91 per share, an increase of ¥1 from the previous fiscal year.